Start Receiving Updates
Fill out this form to receive updates about INBRIJA.
Your Request has Been Submitted!
Stay tuned. A representative will get in touch with you!
Go to homepageFill out this form to receive updates about INBRIJA.
Stay tuned. A representative will get in touch with you!
Go to homepageIntermittent treatment of OFF episodes in patients with PD treated with CD/LD.
Contraindicated in patients taking or who have recently taken (within 2 weeks) nonselective monoamine oxidase (MAO) inhibitors (e.g., phenelzine and tranylcypromine) due to hypertension risk. Discontinue use of nonselective MAO inhibitors at least 2 weeks prior to initiating INBRIJA.
INBRIJA is indicated for intermittent treatment of OFF episodes in patients with Parkinson’s disease (PD) treated with carbidopa/levodopa.
Please see the Full Prescribing Information.
Please Note: By clicking on this link, you are about to leave Inbrija-HCP.com, a website owned and operated by Acorda Therapeutics, Inc.
Acorda Therapeutics, Inc. provides these links as a service to its website visitors and users; however, it does not endorse or take any responsibility for the information presented on any websites but its own.
No thanks, I'll stay Take me thereYou are sharing
:The information you provide will be used by Acorda Therapeutics, Inc. in accordance with our Privacy Policy and by parties acting on Acorda's behalf to send them information on INBRIJA. View our Privacy Policy.
Diagnosed: 2015 at age 57
Career: A board member for several not-for-profit organizations
Issue: When OFF, she slows down, has trouble standing up straight, starts to shuffle steps, and finds it harder to perform routine motions
Utilizes INBRIJA: Approximately 10 times per week
One dose = 2 capsules. No more than 1 dose per OFF period. May be taken as needed up to a maximum of 5 doses per day
Diagnosed: 2007 at age of 39
Issue: Despite an optimized baseline regimen, Jimmy frequently experiences a return of symptoms before his next scheduled dose of CD/LD including muscle rigidity, tremors, shaking, difficulty talking and unable to walk due to being locked up.
Utilizes INBRIJA: 2-3 times per day on average weekday, increases to 4 - 5 times on weekends depending on activity level
One dose = 2 capsules. No more than 1 dose per OFF period. May be taken as needed up to a maximum of 5 doses per day
Our Statement on COVID-19
March 26, 2020
Since the initial outbreak of COVID-19, Acorda has been closely monitoring our supply chain for potential impact to the supply of our medicines. Acorda manufactures INBRIJA® (levodopa inhalation powder) in the United States and sources active pharmaceutical ingredient (API) from Japan. INBRIJA continues to be available through a dedicated specialty pharmacy network. Acorda communicates with these dedicated pharmacies on a daily basis or as frequently as needed to ensure that all eligible patients continue to have uninterrupted access to their INBRIJA. All patient support services remain active and can be offered without interruption.
05/20 INB8868